While DKA is rare with GLP-1 receptor agonists, cases have been reported, particularly when concomitant insulin is rapidly reduced or discontinued
Research on patients using transdermal patches for neurological conditions concluded that adherence rates increased to 85.9% gradually, with patch users more likely to continue treatment than those on oral medication
Generally, the cap may end after a patient has used the drug for more than a year, which is usually enough time to know that it works
Ozempic vs Tirzepatide: Comparing Two Medical Weight Loss Treatments Ozempic and Tirzepatide are both GLP-1 receptor agonists used for weight loss, but they work differently
Step 5: Smart Transition Weight Care Program After you've started with your GLP-1 solution, your Physician will track your progress and provide you with additional weight care and nutrition counseling
Early results from the TRIUMPH-1 Phase 3 clinical trial reveal promising outcomes, with participants losing up to 28.3% of their body weight over an 80-week period
